bad luck [Study As­sess­ment]

posted by Dr_Dan  – Germany, 2013-05-27 14:28 (4773 d 20:42 ago) – Posting: # 10662
Views: 16,547

Dear wxp
a BE study is a pivotal study and so unfortunately it will not be possible to add another group of subjects since this has to be pre-specified in the protocol. Furthermore appropriate steps to preserve the overall type I error (patient’s risk) have to be considered.
For further information please see Potvin D, Diliberti CE, Hauck WW, Parr AF, Schuirmann DJ, and RA Smith: Sequential design approaches for bioequivalence studies with crossover designs. Pharmaceut Statist 7/4, 245–62 (2008)
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,572 registered users;
137 visitors (0 registered, 137 guests [including 32 identified bots]).
Forum time: 11:11 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5